Edition:
United States

Baxter International Inc (BAX)

BAX on New York Consolidated

50.39USD
23 Feb 2017
Change (% chg)

$0.33 (+0.66%)
Prev Close
$50.06
Open
$50.25
Day's High
$50.76
Day's Low
$50.06
Volume
1,828,592
Avg. Vol
3,609,625
52-wk High
$50.76
52-wk Low
$37.69

Select another date:

Thu, Feb 16 2017

BRIEF-Baxter debuts enteral nutrition ENFit syringe and accessory line in clinical nutrition week 2017

* Baxter debuts enteral nutrition ENFit syringe and accessory line during clinical nutrition week 2017

BRIEF-Baxter appoints Stephen Oesterle to its board

* Appointment brings total number serving on board to 12 Source text for Eikon: Further company coverage:

BRIEF-Baxter's renal therapy services significantly reduced peritonitis infections among home dialysis patients

* Baxter's renal therapy services significantly reduced peritonitis infections among home dialysis patients

Baxter to pay $18 million over mold at North Carolina plant

WASHINGTON Baxter International has agreed to pay $18 million to resolve its criminal and civil liability over claims its unit ignored mold in air filters at a plant where sterile intravenous solutions were made, the U.S. Justice Department said on Thursday.

UPDATE 2-Baxter to pay $18 mln over mold at North Carolina plant

WASHINGTON, Jan 12 Baxter International has agreed to pay $18 million to resolve its criminal and civil liability over claims its unit ignored mold in air filters at a plant where sterile intravenous solutions were made, the U.S. Justice Department said on Thursday.

BRIEF-Baxter presented exploratory research on the removal of inflammation-related molecules during extracorporeal blood purification therapy

* Baxter International Inc - presented exploratory research on the removal of inflammation-related molecules during extracorporeal blood purification therapy

BRIEF-Baxter declares quarterly dividend and announces expanded share repurchase authorization

* Baxter declares quarterly dividend and announces expanded share repurchase authorization

BRIEF-Baxter Q3 adj earnings per share $0.56 from continuing operations excluding items

* Baxter reports third quarter 2016 results and increases financial outlook for full-year 2016

Fitch Affirms Baxter International Inc.'s IDR at 'BBB+'; Outlook Stable

(The following statement was released by the rating agency) CHICAGO, October 03 (Fitch) Fitch Ratings has affirmed Baxter International Inc.'s (BAX/Baxter) Long-Term Issuer Default Rating at 'BBB+'. The Rating Outlook is Stable. Baxter had approximately $3.2 billion in outstanding debt at June 30, 2016. A full list of Baxter's ratings follows at the end of this release. KEY RATING DRIVERS --The 'BBB+' rating reflects Baxter's significant deleveraging and strong operating performance post th

Select another date:

More From Around the Web